Business Wire

Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD ® Use During the COVID-19 Pandemic

Share

Not intended for UK and U.S. based media

Merck, a leading science and technology company, today announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis (RMS) treated with MAVENCLAD® (cladribine tablets), which may contribute to their ability to fight infections and develop protective antibodies from vaccines. The data were presented at the 2021 American Academy of Neurology (AAN) Annual Meeting that was held virtually 17-22 April 2021.

In the MAGNIFY-MS study, reduction of memory B cells occurred as early as one month after MAVENCLAD initiation with lowest levels sustained for up to 12 months, while naïve B cells, which are typically required for the generation of antibody responses following vaccination, began recovering immediately. Previously shared data from MAGNIFY-MS indicated that patients receiving MAVENCLAD are able to mount responses to influenza and varicella zoster vaccines, irrespective of lymphocyte count.

“The findings presented at AAN further our understanding of how MAVENCLAD impacts the immune system, and how it may exert a therapeutic effect in patients with multiple sclerosis while repopulating cells which support immune responses,” said Heinz Wiendl, MD, Department of Neurology with Institute of Translational Neurology, University of Muenster, Germany. “These important data indicate that in addition to addressing MS relapses and progression, patients treated with MAVENCLAD may be able to simultaneously mount a proper vaccine response – a particularly important finding at this time.”

In addition, a recent independent study conducted by Anat Achiron, MD, PhD, FAAN and colleagues, The Multiple Sclerosis Center at Sheba Medical Centre and Sackler School of Medicine Tel Aviv University, Israel, and recently published in Therapeutic Advances in Neurological Disorders, shows that patients who have taken MAVENCLAD were able to generate COVID-19 antibodies following the mRNA vaccine from Pfizer/BioNTech administered 4.4 months after last MAVENCLAD dosing. The observational analysis showed that all 23 relapsing-remitting MS patients treated with MAVENCLAD who received the Pfizer/BioNTech mRNA vaccine developed a protective SARS-COV-2 IgG antibody response [antibody titer >1.1 is considered positive; median=7.0], which was similar to the comparison group of MS patients not receiving any immunomodulatory treatments and healthy subjects. Humoral response to the COVID-19 vaccine was independent of lymphocyte count. These findings appeared unique to MAVENCLAD across other high-efficacy MS therapies. No unexpected safety findings post first and second dose of Pfizer/BioNTech COVID-19 vaccination were identified in MS patients, according to another recent publication in the Multiple Sclerosis Journal.

“Bringing MAVENCLAD-treated patients into a state where they can live their lives as normally as possible during a global pandemic is of utmost importance to us,” said Danny Bar-Zohar, MD, Global Head of Development, Healthcare business of Merck. “Beyond the convenient oral dosing schedule, proven efficacy, and well-characterized safety profile of MAVENCLAD, newly generated data now show encouraging initial evidence for these patients` ability to generate adequate antibody response to COVID-19 vaccination, which is so important for patients.”

The ability to mount an adequate immune response is critical as the COVID-19 pandemic impacts patients living with chronic disease around the world. As presented at AAN, and also published in MSaRD, an updated post-approval safety analysis provided a look at outcomes from cases of COVID-19 in MAVENCLAD-treated patients. The safety database analysis included cases of confirmed (n=160) or suspected (n=101) COVID-19 in MAVENCLAD-treated patients. Based on the analysis, the majority of patients had mild to moderate respiratory symptoms and none required mechanical ventilation. MAVENCLAD-treated patients had a similar disease course with COVID-19 compared with the general population who acquired COVID-19.

About MAVENCLAD®
MAVENCLAD® is a short-course oral therapy that selectively and periodically targets lymphocytes thought to be integral to the pathological process of relapsing MS (RMS). In August 2017, the European Commission (EC) granted marketing authorization for MAVENCLAD® for the treatment of relapsing forms of multiple sclerosis (RMS) in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland. MAVENCLAD® has since then been approved in over 80 countries, including Canada, Australia and the U.S. Refer to the respective prescribing information for further details.

The clinical development programme for cladribine tablets includes:

  • The CLARITY (Cladribine Tablets Treating MS Orally) study: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of cladribine tablets as a monotherapy in patients with RRMS.
  • The CLARITY extension study: a Phase III placebo-controlled study following on from the CLARITY study, which evaluated the safety and exploratory efficacy of cladribine tablets over two additional years beyond the two-year CLARITY study, according to the treatment assignment scheme for years 3 and 4.
  • The ORACLE MS (Oral Cladribine in Early MS) study: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of cladribine tablets as a monotherapy in patients at risk of developing MS (patients who have experienced a first clinical event suggestive of MS).
  • The ONWARD (Oral Cladribine Added ON to Interferon beta-1a in Patients With Active Relapsing Disease) study: a Phase II placebo-controlled study designed primarily to evaluate the safety and tolerability of adding cladribine tablets treatment to patients with relapsing forms of MS, who have experienced breakthrough disease while on established interferon-beta therapy.
  • PREMIERE (Prospective Observational Long-term Safety Registry of Multiple Sclerosis) study: a long-term observational follow-up safety registry of MS patients who participated in cladribine tablets clinical studies.

In the two-year CLARITY study, the most commonly reported adverse event (AE) in patients treated with cladribine tablets was lymphopenia (26.7% with cladribine tablets and 1.8% for placebo). The incidence of infections was 48.3% with cladribine tablets and 42.5% with placebo, with 99.1% and 99.0% respectively rated mild-to-moderate by investigators. Adverse Events reported in other clinical studies were similar.

About the MAGNIFY-MS sub-study
The MAGNIFY-MS sub-study was conducted to evaluate the peripheral immune cell subset dynamics and repopulation patterns in the first 12 months of MAVENCLAD therapy in 57 patients. Absolute cell counts and percent change from baseline were assessed for adaptive immune cell subtypes and immunoglobulins. Results found that there is an early onset of action, with most B cell subtypes reaching nadir (or lowest achieved) levels by month two. T cell subtypes showed reductions at later time points (mainly between months three and six) and no changes were seen for other natural killer (NK) cell subtypes. Reduction in memory B cells was sustained to month 12; regulatory B cells recovered by month three, and then increased over baseline levels.

About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.8 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

Merck in Neurology and Immunology
Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company`s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck`s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE).

All Merck Press Releases are distributed by email at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service

About Merck
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science and EMD Electronics.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tone B. Fritzen
tone-brauti.fritzen@merckgroup.com
+49 151 1454 2694

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Data From Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress12.5.2021 22:18:00 CEST | Press release

Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming European Hematology Association (EHA) 2021 Virtual Congress, held virtually from June 9-17, 2021. “We are pleased that data highlighting the strength of Incyte’s oncology portfolio and partner-sponsored programs will be presented at this year’s EHA Virtual Congress,” said Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapeutics, Incyte. “In particular, data being presented at the congress – including the first presentation of data from our Phase 2 study of parsaclisib, our PI3kδ inhibitor, in autoimmune hemolytic anemia; an oral presentation on real-world data for ruxolitinib, our JAK1/JAK2 inhibitor; and an ePoster from our Phase 2 combination study of ruxolitinib and parsaclisib in patients with myelofibrosis – reinforce our commitment to finding solutions for patients with significant unmet medical needs.” Key abstracts ac

Monument Assurance Luxembourg Acquires AME Life Luxembourg ("AMELL") From Covéa12.5.2021 21:55:00 CEST | Press release

Monument Re announced today that, subject to necessary regulatory approval, Monument Assurance Luxembourg will acquire AME Life Luxembourg (“AMELL”) from French Mutual Insurance Group Covéa. AMELL is a well-established Luxembourg-based life insurance company with market presence in Luxembourg, Belgium and Italy. Financial terms of the transaction were not disclosed. The transaction will have no impact on AMELL clients and policyholders. “We are pleased to have reached agreement with Covéa to acquire its subsidiary AMELL. This transaction represents an important step in our consolidation strategy by further strengthening our presence in Luxembourg,” said Manfred Maske, CEO of Monument Re. Change of control of the company will follow satisfaction of customary closing conditions, including receipt of regulatory approvals. For further information: To learn more, please visit our website at www.monumentregroup.com or contact Fiona Davies at info@monumentregroup.com, +1(441) 400-9300. Monume

Raven Industries Launches the OMNi Brand12.5.2021 15:15:00 CEST | Press release

Raven Industries, Inc.(the Company; NASDAQ:RAVN) a leader in agriculture technology, announced today the launch of its new product brand and autonomous growth platform, OMNi. This new product brand highlights Raven’s advancements in autonomous solutions for agriculture with a strategic offering of two integrated products: OMNiDRIVE™ and OMNiPOWER™. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210512005126/en/ The OMNi name (meaning "all") will take center stage within Raven. “Empowering ‘all’ is exactly what OMNiPOWER™ and OMNiDRIVE™ bring to the agriculture industry. OMNi enables holistic, hands-free precision; it gives the farmer total control of their time and maximizes operational productivity and efficiency,” said Nick Langerock, Director of Strategic Marketing for Raven. “As we bring OMNi to market, we want farmers to understand that some of their pain points are now more manageable through autonomous solutions. OMNi

SentinelOne Receives Highest Score for the Type A Use Case (“Lean Forward” Organizations) in the Gartner 2021 Critical Capabilities for Endpoint Protection Platforms12.5.2021 15:00:00 CEST | Press release

SentinelOne, the autonomous cybersecurity platform company, today announced that Gartner has positioned SentinelOne with the highest score in use case Type A in Gartner’s 2021 Critical Capabilities for Endpoint Protection Platforms report1. SentinelOne received the highest score for all three customer types out of 19 vendors. Gartner says, “Type A organizations, also referred to as 'lean forward' organizations, adopt new technologies very early in the adoption cycle.” “We believe receiving the highest product score among early technology adopters in the 2021 Critical Capabilities for Endpoint Protection Platforms validates our commitment to disrupt and broaden the endpoint space,” said Raj Rajamani, Chief Product Officer, SentinelOne. “These organizations tend to focus on innovative solutions that address their business, technology and security needs. Receiving the highest score for 'lean forward' companies highlights our ability to take cybersecurity defenses to new levels of speed, e

New CloudBlue Revenue Management Solution Solves for Recurring Billing Reconciliation12.5.2021 15:00:00 CEST | Press release

CloudBlue, a leading cloud ecosystem technology company, announced today the launch of CloudBlue Rev, a solution that enables partners to ‘rev’ up their channel revenue management. CloudBlue Rev simplifies and streamlines channel revenue management to enhance efficiency, save time and increase profitability. Available now in the United Kingdom with planned rollouts across the world, learn more here. The new solution is based on the recently acquired HarmonyPSA architecture and is the latest addition to CloudBlue’s rapidly expanding portfolio of technologies and services for the channel. CloudBlue Rev helps channel reseller partners regain valuable time as they transition to an everything-as-a-service business by automating quoting, billing and reconciliation. By streamlining these processes into a single platform, resellers will now be able to automate profit tracking across sales motions with integrated discounting and markup, as well as quickly set margins and gain insight into contr

Hiro Capital Leads $6.4m Investment in Game Innovators Twin Suns Corp and FRVR12.5.2021 15:00:00 CEST | Press release

Twin Suns Corp and FRVR will use Hiro’s $6.4m of investment to expand development and to accelerate growth. Twin Suns Corp is a new AAA-game studio, founded by >20-year industry veterans - Tim Longo Jr. (Star Wars: Republic Commando, Halo, Tomb Raider), Forest Swartout Large (Hitman and Tomb Raider), and Jeff Morris (Gears of War and Unreal Tournament). Twin Suns Corp is building a next-gen AAA cross-platform title that will launch an exciting new IP franchise; with additional team members that have worked on Star Wars, Tomb Raider, Hitman, Halo, Elder Scrolls, Fallout, Gears of War, Unreal Tournament and Avengers. FRVR is an instant games ecosystem platform powering frictionless game play on any device, founded by Chris Benjaminsen (Yahoo, PlayerScale) and Brian Meidell (Cape, GameAnalytics) With more than 1bn players, FRVR has partnerships that puts their tech and games onto billions of devices. Twin Suns Corp and FRVR join other creator-founded Games teams Polyarc, Snowprint, Lightf

Nuclera Acquires E Ink Digital Microfluidics Unit12.5.2021 14:53:00 CEST | Press release

Nuclera, a fast-growing biotech company developing enzymatic protein and gene synthesis technologies, and E Ink, the leading innovator of electronic ink technology, are pleased to announce the acquisition of E Ink’s digital microfluidics unit into the newly formed US subsidiary of Nuclera. Combining the technologies of the two companies will enable the delivery of a revolutionary desktop protein and gene “bioprinter” with breakthrough speed and convenience for researchers in human health, agriculture, and other markets of global importance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210512005575/en/ Nuclera desktop bioprinter powered by digital microfluidic technology. (Photo: Business Wire) Nuclera has been working in a strategic partnership with E Ink since 2018 to deploy Nuclera’s proprietary biopolymer synthesis technologies on E Ink’s digital microfluidic devices. Instead of the physical channels found in convention